The 6th Annual Pharma Pricing and Reimbursement Forum 2017 covers topics such as:
- Importance of cost-containment and risk-sharing with austerity striking the whole European economy
- The pan-European situation of pharma industry
- How to handle the growing HTA say in P&R?
- The 4th hurdle of P&R, latest developments
- Pharmacists’ view
- Newest Pharma Policies and recent regulations affect market access
- Germany’s 2-year experience with AMNOG
- P& R strategies of the Big Five, influence on each other’s market
- Italy under construction; Saying goodbye to AIFA-system?
- Value-Based Pricing introduced in the United Kingdom
- French ITR system expectations
- Spain’s transparency and monetary issues
- Oncology, wasting governmental budget or a branch of pharma industry to prosper?
- International problems of innovating
- Russia and Croatia through P&R eyes
The 6th Annual Pharma Pricing and Reimbursement Forum 2017 brings together:
- Payers and policy makers
- Pharmaceutical companies
- Vice Presidents
- Non-industry stakeholders: Senior Vice Presidents
- Directors
- Heads
- Managers of: Pricing and Reimbursement
- Senior managers
- Commercial Pricing
- Market Access
- Health Economics
- Pricing Strategists
- Regulatory Affairs
- Outcome Research
- Public Affairs
- Governmental Affairs
- Health Outcome
- Health Policy
- Public Policy
- HTA
- Regulatory Bodies
- Governmental
